Fig. 1 · Structure

Documents & Downloads

PD0166285

Cat. No. A15863 CAS 185039-89-8

Wee1/Chk inhibitor

PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.

In Stock

Publications for PD0166285

1 publication citing this product

  1. Trang H. Nguyen Vu, .et al. , Cancer Sci, 2023, Dec; 114(12): 4664-4676 PMID: 37724648

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PD0166285 has been used to perturb the WEE1/PKMYT1–CDK1 checkpoint. It reduced Cdc2 Tyr15 phosphorylation in B16 cells and relieved bortezomib-induced G2 accumulation in SNU449 cells. These cellular findings do not establish exclusive WEE1 selectivity. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Wee1 24 nM
Myt1 72 nM
Chk1 3.4 μM

Cellular Effect

Cell Line Activity Value Description Reference
C6 IC50 0.005 μM Inhibition of PDGF-stimulated Platelet-derived growth factor receptor autophosphorylation in C6 rat glioma cells after 2 hr [PMID: 9784112]
C6 IC50 0.12 μM C6 glioma 3-day proliferation followed by soft agar growth with continuous treatment [PMID: 9784112]
C6 IC50 1.8 μM C6 glioma 3-day proliferation followed by soft agar growth without treatment [PMID: 9784112]
HEK293 IC50 7.2 nM Binding affinity to human full-length His-tagged Myt1 kinase expressed in HEK293 cells by TR-FRET based binding assay [PMID: 22770610]
HEK-293T IC50 0.29 μM Antiproliferative activity against HEK293T cells measured after 72 hrs by CellTiter-Blue assay [PMID: 28792760]
MDA-MB-231 IC50 0.16 μM Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by CellTiter-Blue assay [PMID: 28792760]
MM1.S IC50 0.52 μM Antiproliferative activity against human MM1S cells measured after 72 hrs by CellTiter-Blue assay [PMID: 28792760]
NIH3T3 IC50 0.35 μM Inhibition of NIH3T3 proliferation by sulforhodamine B assay [PMID: 9703473]

PD0166285 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of PD0166285 from 2 published references. In vitro models include B16 mouse melanoma cells in culture; SNU449 human hepatoma cells.

PD0166285 In Vitro Studies

In B16 mouse melanoma cells, 0.5 μM PD0166285 increased the G0/G1 fraction from 67% to 86% and reduced the G2 fraction from 17% to 2% at 4 h. No apoptotic sub-G1 population was reported through 24 h, which does not establish overall cell survival. [1]

In SNU449 cells pretreated with 20 nM bortezomib for 18 h, adding 0.5 μM PD0166285 for 2 h relieved G2 arrest more strongly than MK-1775. Rabusertib and prexasertib failed to relieve the arrest in this comparison. [2]

Cell-cycle redistribution and Cdc2 phosphorylation in B16 cells

Cell-based study · B16 mouse melanoma cells in culture [1]

At 0.5 μM, PD0166285 shifted cells toward G0/G1 within 4 h and reduced Cdc2 Tyr15 phosphorylation. No apoptotic sub-G1 population was reported through 24 h; this endpoint does not establish overall cell survival.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
G0/G1, S and G2 fractionsReported observation 0 h: 67%, 16%, 17%; 4 h: 86%, 12%, 2%[1]
Cdc2 Tyr15 phosphorylationReported observation Marked reduction after treatment; total Cdc2 remained similar[1]
Apoptotic sub-G1 populationReported observation No sub-G1 population reported at 24 h[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 μM
Exposure duration
0–4 h for redistribution/immunoblot; 24 h only for sub-G1 observation
Method
PI DNA-content flow cytometry and immunoblotting
Vehicle
DMSO control
Co-treatment
Single agent
Reported limits
Selected phase percentages lack a stated replicate count/uncertainty. Salt and lot characterization not specified.
Methods and source locations

Compound reported in the paper: PD0166285; Compound label in the paper: PD0166285

Named research compound in the reported model; no Adooq lot equivalence established.

Methods: Drug, Cell counting, Flow Cytometry and Cell Cycle Analysis, Immunoblotting; Results first/third subsections; Figures 1B and 3A; Discussion

G0/G1, S and G2 fractions: PI flow cytometry; at least 20,000 cells collected per analysis, not a biological replicate count. — Results first subsection; Figure 1B

Cdc2 Tyr15 phosphorylation: Immunoblot at 0, 2 and 4 h; total Cdc2 and actin controls shown. — Results third subsection; Figure 3A and caption

Apoptotic sub-G1 population: DNA-content flow cytometry; absence of this signal does not demonstrate viability. — Results first subsection; Figure 1B; Discussion

Release of bortezomib-induced G2 arrest in SNU449 cells

Cell-based study · SNU449 human hepatoma cells [2]

PD0166285 reduced bortezomib-induced G2 accumulation and increased M-phase cells. MK-1775 had a weaker effect; rabusertib and prexasertib did not relieve the G2 arrest.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-cycle fractions after sequential inhibitor treatmentReported observation PD0166285 decreased G2 and increased M-phase cells relative to bortezomib alone, more strongly than MK-1775. Rabusertib and prexasertib did not relieve G2 arrest.[2]

Literature-Reported Treatment Conditions

Treatment concentration
20 nM bortezomib pretreatment; 0.5 μM PD0166285
Exposure duration
Bortezomib for 18 h, followed by inhibitor addition for another 2 h
Method
pH3-S10/PI staining and FACS
Vehicle
Vehicle control shown; composition not specified in selected cell methods/caption
Co-treatment
Sequential bortezomib plus PD0166285; matched vehicle/single-agent and alternative inhibitor comparisons
Reported limits
Exact phase fractions not transcribed from bars. Cell-experiment vehicle composition and salt not specified.
Methods and source locations

Compound reported in the paper: PD0166285; Compound label in the paper: PD0166285

Named research compound in the reported model; no Adooq lot equivalence established.

Results Sec5; Figure 3b,c and caption; Methods Cell cycle analysis; MOESM1 reagent paragraph

Cell-cycle fractions after sequential inhibitor treatment: pH3-S10/PI flow cytometry; error bars SEM from at least three independent experiments; one-way ANOVA. — Figure 3b,c and caption; Results Sec5

PD0166285 In Vivo Studies

In established HeLa xenografts, intraperitoneal PD0166285 (0.26 mg/kg) combined with bortezomib (0.65 mg/kg), given every three days, reduced tumor growth and terminal tumor weight more than either single agent. The late-treatment groups contained 3–4 mice each. [2]

Bortezomib combination in established HeLa xenografts

Animal study · Established subcutaneous HeLa xenografts in female BALB/c nude mice; treatment started at ~50 mm³ [2]

PD0166285 plus bortezomib suppressed tumor growth and terminal tumor weight more than either drug alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serial tumor volume and terminal tumor weightReported observation Combination suppressed both endpoints more strongly than either single agent[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every three days
Treatment course
Started at ~50 mm³; exact HeLa administration count unresolved
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle
PBS
PBS and both single-agent groupsReference tumor-growth group; n = 3.[2]
Bortezomib alone
Bortezomib 0.65 mg/kg
PBS and both single-agent groupsTumor growth greater than with combination; n = 3.[2]
PD0166285 alone
PD0166285 0.26 mg/kg
PBS and both single-agent groupsTumor growth greater than with combination; n = 3.[2]
Bortezomib plus PD0166285
Bortezomib 0.65 mg/kg plus PD0166285 0.26 mg/kg
PBS and both single-agent groupsLower tumor growth and terminal weight than either single agent; n = 4.[2]
Vehicle
Model: Established HeLa xenografts in female BALB/c nude mice
Reported limits: Methods report five or six administrations across HeLa/Hepa1-6 models without explicit assignment. Supplementary timeline image could not be viewed.
Bortezomib alone
Model: Established HeLa xenografts in female BALB/c nude mice
Reported limits: Methods report five or six administrations across HeLa/Hepa1-6 models without explicit assignment. Supplementary timeline image could not be viewed.
PD0166285 alone
Model: Established HeLa xenografts in female BALB/c nude mice
Reported limits: Methods report five or six administrations across HeLa/Hepa1-6 models without explicit assignment. Supplementary timeline image could not be viewed.
Bortezomib plus PD0166285
Model: Established HeLa xenografts in female BALB/c nude mice
Reported limits: Methods report five or six administrations across HeLa/Hepa1-6 models without explicit assignment. Supplementary timeline image could not be viewed.
Methods and source locations

Compound reported in the paper: PD0166285; Compound label in the paper: PD0166285

Named research compound in the reported model; no Adooq lot equivalence established.

Results Sec6; Figure 6d,e and caption; Methods Sec23 Mouse subcutaneous xenograft models; MOESM1 reagent paragraph and Supplementary Figure 9 caption

Serial tumor volume and terminal tumor weight: Caliper volume = length × width²/2, measured every three days; terminal weighing. n = 3/3/3/4 for vehicle/BTZ/PD0166285/combination. Figure caption specifies two-way ANOVA for growth and one-way ANOVA for weight. — Figure 6d,e and caption; Results Sec6; Methods Sec23

Vehicle · Results Sec6; Figure 6d,e and caption; Methods Sec23 Mouse subcutaneous xenograft models; MOESM1 reagent paragraph and Supplementary Figure 9 caption

Bortezomib alone · Results Sec6; Figure 6d,e and caption; Methods Sec23 Mouse subcutaneous xenograft models; MOESM1 reagent paragraph and Supplementary Figure 9 caption

PD0166285 alone · Results Sec6; Figure 6d,e and caption; Methods Sec23 Mouse subcutaneous xenograft models; MOESM1 reagent paragraph and Supplementary Figure 9 caption

Bortezomib plus PD0166285 · Results Sec6; Figure 6d,e and caption; Methods Sec23 Mouse subcutaneous xenograft models; MOESM1 reagent paragraph and Supplementary Figure 9 caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 185039-89-8
Applications Wee1/Chk inhibitor
Formula C26H27Cl2N5O2
Molecular Weight 512.43
SMILES
CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (177.58 mM)
Water Insoluble
Ethanol 91 mg/mL (177.58 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PD0166285 Research References

  1. [1] Hashimoto O, Shinkawa M, Torimura T, et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line BMC cancer (2006). PMID: 17177986 DOI: 10.1186/1471-2407-6-292 Source material
  2. [2] Chen ZL, Xie C, Zeng W, et al. Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases Signal transduction and targeted therapy (2024). PMID: 38992067 DOI: 10.1038/s41392-024-01896-z Source material

Publications

1 publication citing this product

  1. Trang H. Nguyen Vu, .et al. , Cancer Sci, 2023, Dec; 114(12): 4664-4676 PMID: 37724648

Added to your cart

View Cart Checkout
Loading...